|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC35G2 |
Gene summary for SLC35G2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC35G2 | Gene ID | 80723 |
| Gene name | solute carrier family 35 member G2 | |
| Gene Alias | TMEM22 | |
| Cytomap | 3q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8TBE7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80723 | SLC35G2 | P61T-E | Human | Esophagus | ESCC | 2.98e-11 | 2.36e-01 | 0.099 |
| 80723 | SLC35G2 | P62T-E | Human | Esophagus | ESCC | 7.87e-06 | 1.56e-01 | 0.1302 |
| 80723 | SLC35G2 | P65T-E | Human | Esophagus | ESCC | 2.19e-10 | 2.56e-01 | 0.0978 |
| 80723 | SLC35G2 | P74T-E | Human | Esophagus | ESCC | 2.70e-33 | 1.06e+00 | 0.1479 |
| 80723 | SLC35G2 | P76T-E | Human | Esophagus | ESCC | 4.54e-05 | 1.15e-01 | 0.1207 |
| 80723 | SLC35G2 | P79T-E | Human | Esophagus | ESCC | 2.10e-07 | 1.90e-01 | 0.1154 |
| 80723 | SLC35G2 | P80T-E | Human | Esophagus | ESCC | 5.03e-06 | 2.11e-01 | 0.155 |
| 80723 | SLC35G2 | P89T-E | Human | Esophagus | ESCC | 8.32e-16 | 9.92e-01 | 0.1752 |
| 80723 | SLC35G2 | P107T-E | Human | Esophagus | ESCC | 6.08e-04 | 8.25e-02 | 0.171 |
| 80723 | SLC35G2 | P130T-E | Human | Esophagus | ESCC | 7.32e-38 | 7.09e-01 | 0.1676 |
| 80723 | SLC35G2 | HCC1_Meng | Human | Liver | HCC | 1.86e-18 | -1.17e-03 | 0.0246 |
| 80723 | SLC35G2 | HCC2_Meng | Human | Liver | HCC | 5.75e-05 | 7.91e-03 | 0.0107 |
| 80723 | SLC35G2 | S014 | Human | Liver | HCC | 1.17e-11 | 4.82e-01 | 0.2254 |
| 80723 | SLC35G2 | S015 | Human | Liver | HCC | 3.44e-19 | 8.44e-01 | 0.2375 |
| 80723 | SLC35G2 | S016 | Human | Liver | HCC | 1.32e-27 | 7.96e-01 | 0.2243 |
| 80723 | SLC35G2 | S027 | Human | Liver | HCC | 1.78e-04 | 4.51e-01 | 0.2446 |
| 80723 | SLC35G2 | S028 | Human | Liver | HCC | 4.31e-23 | 7.00e-01 | 0.2503 |
| 80723 | SLC35G2 | S029 | Human | Liver | HCC | 1.06e-20 | 6.96e-01 | 0.2581 |
| 80723 | SLC35G2 | C30 | Human | Oral cavity | OSCC | 4.57e-05 | 2.94e-01 | 0.3055 |
| 80723 | SLC35G2 | C38 | Human | Oral cavity | OSCC | 7.50e-11 | 6.85e-01 | 0.172 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC35G2 | SNV | Missense_Mutation | novel | c.911N>G | p.Phe304Cys | p.F304C | Q8TBE7 | protein_coding | deleterious(0.04) | probably_damaging(0.957) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| SLC35G2 | SNV | Missense_Mutation | novel | c.1004T>C | p.Val335Ala | p.V335A | Q8TBE7 | protein_coding | tolerated(0.26) | probably_damaging(0.989) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC35G2 | SNV | Missense_Mutation | novel | c.812N>T | p.Ser271Leu | p.S271L | Q8TBE7 | protein_coding | tolerated(0.05) | benign(0.259) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
| SLC35G2 | SNV | Missense_Mutation | novel | c.983N>T | p.Ser328Phe | p.S328F | Q8TBE7 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
| SLC35G2 | SNV | Missense_Mutation | novel | c.664G>A | p.Asp222Asn | p.D222N | Q8TBE7 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| SLC35G2 | deletion | Frame_Shift_Del | rs758765963 | c.184delN | p.Arg66GlufsTer18 | p.R66Efs*18 | Q8TBE7 | protein_coding | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SLC35G2 | SNV | Missense_Mutation | novel | c.98N>A | p.Pro33His | p.P33H | Q8TBE7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SLC35G2 | SNV | Missense_Mutation | novel | c.740N>A | p.Ser247Tyr | p.S247Y | Q8TBE7 | protein_coding | deleterious(0.02) | possibly_damaging(0.819) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC35G2 | SNV | Missense_Mutation | rs570589760 | c.382N>T | p.Arg128Trp | p.R128W | Q8TBE7 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SLC35G2 | SNV | Missense_Mutation | c.139N>C | p.Asn47His | p.N47H | Q8TBE7 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |